This paper is only available as a PDF. To read, Please Download here.
Abstract
Significant serum uric acid reductions resulted from the oral administration of 500
and 1000 mg daily doses of halofenate in patients with hyperlipoproteinemia. Pretreatment
serum uric acid levels averaged 8.5 mg/100 ml: serum uric acid levels during placebo
control period averaged 7.7 mg/100 ml. At halofenate doses of 500 mg daily, the mean
level fell to 5.6 mg/100 ml; after 1000 mg to 4.2 mg/100 ml. Urate clearance increased
significantly at both dosage levels. Mean cholesterol levels decreased only slightly;
triglyceride levels fell 16% from placebo levels on the larger dose of halofenate
(1000 mg daily). Halofenate serum concentrations consistently reached a plateau by
the 7th day of administration. There was an initial rapid decline in serum levels
of halofenate immediately after discontinuance of the drug, but traces of it were
still detectable one month later. Serum bilirubin levels decreased in all patients,
possibly as a result of displacement of bilirubin from its plasma binding sites by
halofenate. This study confirms the potent uricosuric action of this recently developed
lipid-lowering drug.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to AtherosclerosisAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The hypolipemic properties of 2-acetoamidoethyl (p-chlorophenyl) (m-trifluoromethylphenoxy) acetate in the rat.in: 4th edition. Proc. Soc. Exp. Biol. Med.136. 1971: 1274-1276
- The effect of MK-185 on some aspects of uric acid metabolism.Clin. Pharmacol. Therap. 1970; 11: 551-557
- Clinical evaluation of MK-185; a new hypolipidemic drug.J. Amer. Oil Chemists Soc. 1971; 48: 92A
- Hypolipidemic, uricosuric, and thyroxine-displacing effects of MK-185 (halofenate).Clin. Pharmacol. Therap. 1971; 12: 517-524
- Multiple range and multiple F test.Biometrics. March, 1955;
- Alteration of factors predisposing to coronary heart disease.Ann. Intern. Med. 1968; 68: 1072-1077
Hutchison, J. C., and Wilkinson, W. H., The dosage, form and mg/K response of halofenate (MK-185) on uric acid and serum lipids, To be published.
- Metabolism of a new hypolipidemic agent, 2-acetamidoethyl (p-chlorophenyl) (m-trifluormethylphenoxy) acetate (halofenate) in the rat, dog, rhesus monkey and man.J. Pharmacol. Exp. Therap. 1971; 179: 359
Article info
Publication history
Received:
August 11,
1972
Identification
Copyright
© 1973 Published by Elsevier Inc.
